Differential down-regulation of HLA-DR on monocyte subpopulations during systemic inflammation

Decreased expression of human leukocyte antigen class II (HLA-DR) on monocytes is a hallmark of altered immune status in patients with a systemic inflammatory response syndrome (SIRS). So far, the analyses were mainly performed without taking into account monocytes subpopulations. We studied this mo...

Full description

Saved in:
Bibliographic Details
Published inCritical care (London, England) Vol. 14; no. 2; p. R61
Main Authors Kim, Oh Yoen, Monsel, Antoine, Bertrand, Michèle, Coriat, Pierre, Cavaillon, Jean-Marc, Adib-Conquy, Minou
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 13.04.2010
National Library of Medicine - MEDLINE Abstracts
BioMed Central
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Decreased expression of human leukocyte antigen class II (HLA-DR) on monocytes is a hallmark of altered immune status in patients with a systemic inflammatory response syndrome (SIRS). So far, the analyses were mainly performed without taking into account monocytes subpopulations. We studied this modification on CD14HIGH and CD14LOW monocytes of 20 SIRS patients undergoing abdominal aortic surgery (AAS), 20 patients undergoing carotid artery surgery (CAS), and 9 healthy controls, and we investigated mediators and intracellular molecules that may be involved in this process. HLA-DR on CD14HIGH monocytes started to decrease during surgery, after blood reperfusion, and was further reduced post-surgery. In contrast, HLA-DR expression on CD14LOW cells only decreased after surgery, and to a lesser extent than on CD14HIGH monocytes. Negative correlations were found between the reduction of HLA-DR expression and the change in cortisol levels for both subpopulations, whereas a negative correlation between interleukin-10 (IL-10) levels and HLA-DR modulation was only observed for CD14HIGH cells. In accordance with these ex vivo results, HLA-DR on CD14HIGH and CD14LOW monocytes of healthy donors was reduced following incubation with hydrocortisone, whereas IL-10 only acted on CD14HIGH subpopulation. Furthermore, flow cytometry revealed that the expression of IL-10 receptor was higher on CD14HIGH versus CD14LOW monocytes. In addition, hydrocortisone, and to a lesser extent IL-10, reversed the up-regulation of HLA-DR induced by bacterial products. Finally, membrane-associated RING-CH-1 protein (MARCH1) mRNA, a negative regulator of MHC class II, was up-regulated in monocytes of AAS patients on Day 1 post-surgery, and in those of healthy subjects exposed to hydrocortisone. This study reveals that HLA-DR expression is modulated differently on CD14HIGH (classical) versus CD14LOW (inflammatory) monocytes after systemic inflammation.
AbstractList Decreased expression of human leukocyte antigen class II (HLA-DR) on monocytes is a hallmark of altered immune status in patients with a systemic inflammatory response syndrome (SIRS). So far, the analyses were mainly performed without taking into account monocytes subpopulations.INTRODUCTIONDecreased expression of human leukocyte antigen class II (HLA-DR) on monocytes is a hallmark of altered immune status in patients with a systemic inflammatory response syndrome (SIRS). So far, the analyses were mainly performed without taking into account monocytes subpopulations.We studied this modification on CD14HIGH and CD14LOW monocytes of 20 SIRS patients undergoing abdominal aortic surgery (AAS), 20 patients undergoing carotid artery surgery (CAS), and 9 healthy controls, and we investigated mediators and intracellular molecules that may be involved in this process.METHODSWe studied this modification on CD14HIGH and CD14LOW monocytes of 20 SIRS patients undergoing abdominal aortic surgery (AAS), 20 patients undergoing carotid artery surgery (CAS), and 9 healthy controls, and we investigated mediators and intracellular molecules that may be involved in this process.HLA-DR on CD14HIGH monocytes started to decrease during surgery, after blood reperfusion, and was further reduced post-surgery. In contrast, HLA-DR expression on CD14LOW cells only decreased after surgery, and to a lesser extent than on CD14HIGH monocytes. Negative correlations were found between the reduction of HLA-DR expression and the change in cortisol levels for both subpopulations, whereas a negative correlation between interleukin-10 (IL-10) levels and HLA-DR modulation was only observed for CD14HIGH cells. In accordance with these ex vivo results, HLA-DR on CD14HIGH and CD14LOW monocytes of healthy donors was reduced following incubation with hydrocortisone, whereas IL-10 only acted on CD14HIGH subpopulation. Furthermore, flow cytometry revealed that the expression of IL-10 receptor was higher on CD14HIGH versus CD14LOW monocytes. In addition, hydrocortisone, and to a lesser extent IL-10, reversed the up-regulation of HLA-DR induced by bacterial products. Finally, membrane-associated RING-CH-1 protein (MARCH1) mRNA, a negative regulator of MHC class II, was up-regulated in monocytes of AAS patients on Day 1 post-surgery, and in those of healthy subjects exposed to hydrocortisone.RESULTSHLA-DR on CD14HIGH monocytes started to decrease during surgery, after blood reperfusion, and was further reduced post-surgery. In contrast, HLA-DR expression on CD14LOW cells only decreased after surgery, and to a lesser extent than on CD14HIGH monocytes. Negative correlations were found between the reduction of HLA-DR expression and the change in cortisol levels for both subpopulations, whereas a negative correlation between interleukin-10 (IL-10) levels and HLA-DR modulation was only observed for CD14HIGH cells. In accordance with these ex vivo results, HLA-DR on CD14HIGH and CD14LOW monocytes of healthy donors was reduced following incubation with hydrocortisone, whereas IL-10 only acted on CD14HIGH subpopulation. Furthermore, flow cytometry revealed that the expression of IL-10 receptor was higher on CD14HIGH versus CD14LOW monocytes. In addition, hydrocortisone, and to a lesser extent IL-10, reversed the up-regulation of HLA-DR induced by bacterial products. Finally, membrane-associated RING-CH-1 protein (MARCH1) mRNA, a negative regulator of MHC class II, was up-regulated in monocytes of AAS patients on Day 1 post-surgery, and in those of healthy subjects exposed to hydrocortisone.This study reveals that HLA-DR expression is modulated differently on CD14HIGH (classical) versus CD14LOW (inflammatory) monocytes after systemic inflammation.CONCLUSIONSThis study reveals that HLA-DR expression is modulated differently on CD14HIGH (classical) versus CD14LOW (inflammatory) monocytes after systemic inflammation.
Decreased expression of human leukocyte antigen class II (HLA-DR) on monocytes is a hallmark of altered immune status in patients with a systemic inflammatory response syndrome (SIRS). So far, the analyses were mainly performed without taking into account monocytes subpopulations. We studied this modification on CD14HIGH and CD14LOW monocytes of 20 SIRS patients undergoing abdominal aortic surgery (AAS), 20 patients undergoing carotid artery surgery (CAS), and 9 healthy controls, and we investigated mediators and intracellular molecules that may be involved in this process. HLA-DR on CD14HIGH monocytes started to decrease during surgery, after blood reperfusion, and was further reduced post-surgery. In contrast, HLA-DR expression on CD14LOW cells only decreased after surgery, and to a lesser extent than on CD14HIGH monocytes. Negative correlations were found between the reduction of HLA-DR expression and the change in cortisol levels for both subpopulations, whereas a negative correlation between interleukin-10 (IL-10) levels and HLA-DR modulation was only observed for CD14HIGH cells. In accordance with these ex vivo results, HLA-DR on CD14HIGH and CD14LOW monocytes of healthy donors was reduced following incubation with hydrocortisone, whereas IL-10 only acted on CD14HIGH subpopulation. Furthermore, flow cytometry revealed that the expression of IL-10 receptor was higher on CD14HIGH versus CD14LOW monocytes. In addition, hydrocortisone, and to a lesser extent IL-10, reversed the up-regulation of HLA-DR induced by bacterial products. Finally, membrane-associated RING-CH-1 protein (MARCH1) mRNA, a negative regulator of MHC class II, was up-regulated in monocytes of AAS patients on Day 1 post-surgery, and in those of healthy subjects exposed to hydrocortisone. This study reveals that HLA-DR expression is modulated differently on CD14HIGH (classical) versus CD14LOW (inflammatory) monocytes after systemic inflammation.
Decreased expression of human leukocyte antigen class II (HLA-DR) on monocytes is a hallmark of altered immune status in patients with a systemic inflammatory response syndrome (SIRS). So far, the analyses were mainly performed without taking into account monocytes subpopulations. We studied this modification on CD14HIGH and CD14LOW monocytes of 20 SIRS patients undergoing abdominal aortic surgery (AAS), 20 patients undergoing carotid artery surgery (CAS), and 9 healthy controls, and we investigated mediators and intracellular molecules that may be involved in this process. HLA-DR on CD14HIGH monocytes started to decrease during surgery, after blood reperfusion, and was further reduced post-surgery. In contrast, HLA-DR expression on CD14LOW cells only decreased after surgery, and to a lesser extent than on CD14HIGH monocytes. Negative correlations were found between the reduction of HLA-DR expression and the change in cortisol levels for both subpopulations, whereas a negative correlation between interleukin-10 (IL-10) levels and HLA-DR modulation was only observed for CD14HIGH cells. In accordance with these ex vivo results, HLA-DR on CD14HIGH and CD14LOW monocytes of healthy donors was reduced following incubation with hydrocortisone, whereas IL-10 only acted on CD14HIGH subpopulation. Furthermore, flow cytometry revealed that the expression of IL-10 receptor was higher on CD14HIGH versus CD14LOW monocytes. In addition, hydrocortisone, and to a lesser extent IL-10, reversed the up-regulation of HLA-DR induced by bacterial products. Finally, membrane-associated RING-CH-1 protein (MARCH1) mRNA, a negative regulator of MHC class II, was up-regulated in monocytes of AAS patients on Day 1 post-surgery, and in those of healthy subjects exposed to hydrocortisone. This study reveals that HLA-DR expression is modulated differently on CD14HIGH (classical) versus CD14LOW (inflammatory) monocytes after systemic inflammation.
Decreased expression of human leukocyte antigen class II (HLA-DR) on monocytes is a hallmark of altered immune status in patients with a systemic inflammatory response syndrome (SIRS). So far, the analyses were mainly performed without taking into account monocytes subpopulations. We studied this modification on CD14.sup.HIGH .sup.and CD14.sup.LOW .sup.monocytes of 20 SIRS patients undergoing abdominal aortic surgery (AAS), 20 patients undergoing carotid artery surgery (CAS), and 9 healthy controls, and we investigated mediators and intracellular molecules that may be involved in this process. HLA-DR on CD14.sup.HIGH .sup.monocytes started to decrease during surgery, after blood reperfusion, and was further reduced post-surgery. In contrast, HLA-DR expression on CD14.sup.LOW .sup.cells only decreased after surgery, and to a lesser extent than on CD14.sup.HIGH .sup.monocytes. Negative correlations were found between the reduction of HLA-DR expression and the change in cortisol levels for both subpopulations, whereas a negative correlation between interleukin-10 (IL-10) levels and HLA-DR modulation was only observed for CD14.sup.HIGH .sup.cells. In accordance with these ex vivo results, HLA-DR on CD14.sup.HIGH .sup.and CD14.sup.LOW .sup.monocytes of healthy donors was reduced following incubation with hydrocortisone, whereas IL-10 only acted on CD14.sup.HIGH .sup.subpopulation. Furthermore, flow cytometry revealed that the expression of IL-10 receptor was higher on CD14.sup.HIGH .sup.versus CD14.sup.LOW .sup.monocytes. In addition, hydrocortisone, and to a lesser extent IL-10, reversed the up-regulation of HLA-DR induced by bacterial products. Finally, membrane-associated RING-CH-1 protein (MARCH1) mRNA, a negative regulator of MHC class II, was up-regulated in monocytes of AAS patients on Day 1 post-surgery, and in those of healthy subjects exposed to hydrocortisone. This study reveals that HLA-DR expression is modulated differently on CD14.sup.HIGH .sup.(classical) versus CD14.sup.LOW .sup.(inflammatory) monocytes after systemic inflammation.
INTRODUCTION: Decreased expression of human leukocyte antigen class II (HLA-DR) on monocytes is a hallmark of altered immune status in patients with a systemic inflammatory response syndrome (SIRS). So far, the analyses were mainly performed without taking into account monocytes subpopulations. METHODS: We studied this modification on CD14HIGH and CD14LOW monocytes of 20 SIRS patients undergoing abdominal aortic surgery (AAS), 20 patients undergoing carotid artery surgery (CAS), and 9 healthy controls, and we investigated mediators and intracellular molecules that may be involved in this process. RESULTS: HLA-DR on CD14HIGH monocytes started to decrease during surgery, after blood reperfusion, and was further reduced post-surgery. In contrast, HLA-DR expression on CD14LOW cells only decreased after surgery, and to a lesser extent than on CD14HIGH monocytes. Negative correlations were found between the reduction of HLA-DR expression and the change in cortisol levels for both subpopulations, whereas a negative correlation between interleukin-10 (IL-10) levels and HLA-DR modulation was only observed for CD14HIGH cells. In accordance with these ex vivo results, HLA-DR on CD14HIGH and CD14LOW monocytes of healthy donors was reduced following incubation with hydrocortisone, whereas IL-10 only acted on CD14HIGH subpopulation. Furthermore, flow cytometry revealed that the expression of IL-10 receptor was higher on CD14HIGH versus CD14LOW monocytes. In addition, hydrocortisone, and to a lesser extent IL-10, reversed the up-regulation of HLA-DR induced by bacterial products. Finally, membrane-associated RING-CH-1 protein (MARCH1) mRNA, a negative regulator of MHC class II, was up-regulated in monocytes of AAS patients on Day 1 post-surgery, and in those of healthy subjects exposed to hydrocortisone. CONCLUSIONS: This study reveals that HLA-DR expression is modulated differently on CD14HIGH (classical) versus CD14LOW (inflammatory) monocytes after systemic inflammation.
Introduction Decreased expression of human leukocyte antigen class II (HLA-DR) on monocytes is a hallmark of altered immune status in patients with a systemic inflammatory response syndrome (SIRS). So far, the analyses were mainly performed without taking into account monocytes subpopulations. Methods We studied this modification on CD14.sup.HIGH .sup.and CD14.sup.LOW .sup.monocytes of 20 SIRS patients undergoing abdominal aortic surgery (AAS), 20 patients undergoing carotid artery surgery (CAS), and 9 healthy controls, and we investigated mediators and intracellular molecules that may be involved in this process. Results HLA-DR on CD14.sup.HIGH .sup.monocytes started to decrease during surgery, after blood reperfusion, and was further reduced post-surgery. In contrast, HLA-DR expression on CD14.sup.LOW .sup.cells only decreased after surgery, and to a lesser extent than on CD14.sup.HIGH .sup.monocytes. Negative correlations were found between the reduction of HLA-DR expression and the change in cortisol levels for both subpopulations, whereas a negative correlation between interleukin-10 (IL-10) levels and HLA-DR modulation was only observed for CD14.sup.HIGH .sup.cells. In accordance with these ex vivo results, HLA-DR on CD14.sup.HIGH .sup.and CD14.sup.LOW .sup.monocytes of healthy donors was reduced following incubation with hydrocortisone, whereas IL-10 only acted on CD14.sup.HIGH .sup.subpopulation. Furthermore, flow cytometry revealed that the expression of IL-10 receptor was higher on CD14.sup.HIGH .sup.versus CD14.sup.LOW .sup.monocytes. In addition, hydrocortisone, and to a lesser extent IL-10, reversed the up-regulation of HLA-DR induced by bacterial products. Finally, membrane-associated RING-CH-1 protein (MARCH1) mRNA, a negative regulator of MHC class II, was up-regulated in monocytes of AAS patients on Day 1 post-surgery, and in those of healthy subjects exposed to hydrocortisone. Conclusions This study reveals that HLA-DR expression is modulated differently on CD14.sup.HIGH .sup.(classical) versus CD14.sup.LOW .sup.(inflammatory) monocytes after systemic inflammation.
ArticleNumber R61
Audience Academic
Author Coriat, Pierre
Cavaillon, Jean-Marc
Kim, Oh Yoen
Monsel, Antoine
Adib-Conquy, Minou
Bertrand, Michèle
AuthorAffiliation 1 Unit "Cytokines & Inflammation", Institut Pasteur, 28 rue Dr. Roux, Paris, 75015 France
2 Department of Anesthesiology and Critical Care, Université Pierre et Marie Curie - Paris 6, and Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance-Publique, Hôpitaux de Paris, 47 bd de l'Hôpital, Paris, 75013 France
AuthorAffiliation_xml – name: 1 Unit "Cytokines & Inflammation", Institut Pasteur, 28 rue Dr. Roux, Paris, 75015 France
– name: 2 Department of Anesthesiology and Critical Care, Université Pierre et Marie Curie - Paris 6, and Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance-Publique, Hôpitaux de Paris, 47 bd de l'Hôpital, Paris, 75013 France
Author_xml – sequence: 1
  givenname: Oh Yoen
  surname: Kim
  fullname: Kim, Oh Yoen
– sequence: 2
  givenname: Antoine
  surname: Monsel
  fullname: Monsel, Antoine
– sequence: 3
  givenname: Michèle
  surname: Bertrand
  fullname: Bertrand, Michèle
– sequence: 4
  givenname: Pierre
  surname: Coriat
  fullname: Coriat, Pierre
– sequence: 5
  givenname: Jean-Marc
  surname: Cavaillon
  fullname: Cavaillon, Jean-Marc
– sequence: 6
  givenname: Minou
  surname: Adib-Conquy
  fullname: Adib-Conquy, Minou
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20385017$$D View this record in MEDLINE/PubMed
BookMark eNqFkl1rFDEUhoNU7If6E2RQ0Bun5juZG2Fp1QoLguitIZNJ1pSZZJvMKPvvzXbW2l0UyUU-zpM357w5p-AoxGABeIrgOUKSvzFGNqx5AE4Q4bSWjLCje-tjcJrzNYRISE4egWMMiWRldwK-XXrnbLJh9Lqvuvgz1Mmupl6PPoYquupquagvP1dlM8QQzWa0VZ7adVzvmFx1U_JhVeVNHu3gTeWD6_Uw3EYfg4dO99k-2c1n4Ov7d18ururlpw8fLxbLuuVQjDWlwuLGGcik7pBphWPMlJJESxzBLbRMtJQ2UCCKWIMk0bhz1DaMotY4bMkZeDvrrqd2sJ0p9STdq3Xyg04bFbVX-5Hgv6tV_KGwlKLoFYFmFmh9_IfAfsTEQc2ml7uvdo-neDPZPKrBZ2P7Xgcbp6wE5bD8AqT_JwkhTAiyJZ8fkNdxSqF4qBikHAvR4AK9mKGV7q0qvseSmtlKqgXGXBLOKSrU-V-oMrrtd5U2cr6c7114dt_MOxN-d00BXs6ASTHnZN0dgqDatuMfZ14fgMaPt41RUvD9If4LrLLhmg
CitedBy_id crossref_primary_10_1186_cc10130
crossref_primary_10_3389_fimmu_2023_1210961
crossref_primary_10_1007_s40620_022_01330_z
crossref_primary_10_15360_1813_9779_2019_4_32_41
crossref_primary_10_1126_sciadv_abe3024
crossref_primary_10_1016_j_micinf_2017_12_008
crossref_primary_10_1007_s12026_012_8297_3
crossref_primary_10_1016_j_exger_2014_01_028
crossref_primary_10_1016_j_infect_2014_03_001
crossref_primary_10_1016_j_jointm_2024_01_001
crossref_primary_10_3390_ijms17081316
crossref_primary_10_3389_fcvm_2022_853967
crossref_primary_10_1097_CCM_0000000000000100
crossref_primary_10_1128_IAI_00703_19
crossref_primary_10_3390_biom10040507
crossref_primary_10_4049_jimmunol_1800735
crossref_primary_10_1016_j_tcam_2020_100408
crossref_primary_10_1097_JS9_0000000000001814
crossref_primary_10_3389_fimmu_2024_1454857
crossref_primary_10_1002_art_38860
crossref_primary_10_1002_anie_202113562
crossref_primary_10_1016_S2213_2600_21_00218_6
crossref_primary_10_1371_journal_pone_0293347
crossref_primary_10_2147_JIR_S360207
crossref_primary_10_1097_SHK_0b013e318299ebdd
crossref_primary_10_1186_1471_2164_13_378
crossref_primary_10_4049_jimmunol_2400395
crossref_primary_10_1016_j_patbio_2012_03_011
crossref_primary_10_1016_j_amjsurg_2012_07_042
crossref_primary_10_1186_1471_230X_13_37
crossref_primary_10_1111_anae_14306
crossref_primary_10_1038_s41598_021_91948_z
crossref_primary_10_1002_cyto_a_23098
crossref_primary_10_1002_eji_202350756
crossref_primary_10_1177_1533033818764720
crossref_primary_10_3389_fmolb_2022_1075686
crossref_primary_10_1016_j_jri_2024_104314
crossref_primary_10_15825_1995_1191_2020_2_53_62
crossref_primary_10_1016_j_intimp_2021_108037
crossref_primary_10_4049_jimmunol_1601168
crossref_primary_10_1177_0963689720966265
crossref_primary_10_1371_journal_pone_0169653
crossref_primary_10_1371_journal_pone_0203795
crossref_primary_10_1007_s11357_020_00213_0
crossref_primary_10_1177_0267659115612905
crossref_primary_10_4049_jimmunol_2001191
crossref_primary_10_1016_S1473_3099_19_30567_5
crossref_primary_10_3389_fimmu_2018_01293
crossref_primary_10_1097_SHK_0000000000001314
crossref_primary_10_3390_vaccines9060596
crossref_primary_10_1186_cc13787
crossref_primary_10_3389_fimmu_2021_785941
crossref_primary_10_3389_fimmu_2020_01716
crossref_primary_10_3390_ijms25052900
crossref_primary_10_1016_j_compbiomed_2021_104792
crossref_primary_10_3389_fimmu_2022_807539
crossref_primary_10_1007_s00277_014_2287_6
crossref_primary_10_1189_jlb_5A0516_240R
crossref_primary_10_3390_antiox10091440
crossref_primary_10_1186_s40001_015_0180_y
crossref_primary_10_1007_s12016_023_08965_1
crossref_primary_10_3390_biomedicines11030778
crossref_primary_10_1111_tan_12255
crossref_primary_10_1016_j_crmicr_2023_100215
crossref_primary_10_1016_j_vetimm_2017_06_007
crossref_primary_10_3389_fimmu_2016_00614
crossref_primary_10_3389_fimmu_2020_606649
crossref_primary_10_15252_emmm_201810128
crossref_primary_10_18821_1560_9529_2019_24_3_146_151
crossref_primary_10_3390_ani12162135
crossref_primary_10_1002_JLB_4A0220_114RR
crossref_primary_10_1016_j_egja_2011_07_003
crossref_primary_10_1097_SHK_0000000000001266
crossref_primary_10_1007_s00109_014_1200_z
crossref_primary_10_3390_jcm11092641
crossref_primary_10_1002_iid3_1240
crossref_primary_10_3389_fimmu_2022_1031216
crossref_primary_10_1002_ptr_7345
crossref_primary_10_1186_s12979_020_00191_z
crossref_primary_10_1097_ACO_0b013e32834585d6
crossref_primary_10_1186_s13567_020_00840_7
crossref_primary_10_1002_ange_202113562
Cites_doi 10.1016/0883-9441(91)90032-O
10.1523/JNEUROSCI.16-11-03745.1996
10.1378/chest.112.1.235
10.1016/S1074-7613(03)00174-2
10.1111/j.1365-3083.2007.02051.x
10.1016/0165-5728(95)00080-L
10.1002/eji.200737902
10.1007/s00134-008-1337-8
10.1189/jlb.0806510
10.1007/s00134-004-2429-8
10.1097/01.CCM.0000275271.77350.B6
10.1016/j.jtcvs.2005.01.008
10.1172/JCI115493
10.1002/eji.1830230902
10.1111/j.1365-2044.2009.06161.x
10.1097/01.CCM.0000150958.20209.A3
10.1164/rccm.200203-217OC
10.1016/j.cyto.2006.05.003
10.1038/sj.emboj.7601556
10.1172/JCI30555
10.1002/cyto.b.10031
10.1182/blood.V82.10.3170.3170
10.1086/345675
10.1186/cc7980
10.1080/110241599750008053
10.1097/00003246-200111000-00015
10.1097/00063110-199512000-00003
10.1186/cc5017
10.1073/pnas.0708874105
10.1172/JCI116306
10.1097/01.CCM.0000233875.93866.88
10.4049/jimmunol.162.4.2358
10.1016/1043-4666(93)90034-3
10.1160/TH08-07-0421
10.1016/S1043-4666(03)00090-5
10.1007/s00134-006-0204-8
10.1182/blood.V74.7.2527.2527
10.1164/rccm.200309-1329OC
10.4049/jimmunol.168.7.3536
10.1038/nri1943
10.1016/0002-9610(91)91247-G
10.1097/00024382-200206000-00001
10.1097/00006676-200210000-00006
10.1097/00007890-199706270-00026
10.1002/bjs.1800770225
10.1007/s00134-006-0205-7
10.1510/icvts.2007.158899
ContentType Journal Article
Copyright COPYRIGHT 2010 BioMed Central Ltd.
Copyright National Library of Medicine - MEDLINE Abstracts 2010
Copyright ©2010 Kim et al.; licensee BioMed Central Ltd. 2010 Kim et al.; licensee BioMed Central Ltd.
Copyright_xml – notice: COPYRIGHT 2010 BioMed Central Ltd.
– notice: Copyright National Library of Medicine - MEDLINE Abstracts 2010
– notice: Copyright ©2010 Kim et al.; licensee BioMed Central Ltd. 2010 Kim et al.; licensee BioMed Central Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
7X8
7QL
7T5
C1K
H94
5PM
DOI 10.1186/cc8959
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
Bacteriology Abstracts (Microbiology B)
Immunology Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Immunology Abstracts
Bacteriology Abstracts (Microbiology B)
Environmental Sciences and Pollution Management
DatabaseTitleList MEDLINE - Academic
MEDLINE
ProQuest Health & Medical Complete (Alumni)
AIDS and Cancer Research Abstracts



Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1364-8535
1466-609X
EndPage R61
ExternalDocumentID PMC2887183
oai_biomedcentral_com_cc8959
2062585291
A226836641
20385017
10_1186_cc8959
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations France
GeographicLocations_xml – name: France
GroupedDBID ---
0R~
29F
2WC
4.4
53G
5GY
5VS
6J9
6PF
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ACGFS
ACJQM
ADBBV
ADUKV
AEGXH
AENEX
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
C6C
CITATION
CS3
DIK
E3Z
EBLON
EBS
EJD
F5P
GROUPED_DOAJ
GX1
H13
HYE
IAO
IHR
INH
INR
ITC
KQ8
O5R
O5S
OK1
PIMPY
PQQKQ
RBZ
ROL
RPM
RSV
SJN
SMD
SOJ
TR2
U2A
WOQ
YOC
7X7
88E
8FI
8FJ
ABUWG
AFKRA
BPHCQ
BVXVI
C1A
CCPQU
CGR
CUY
CVF
EBD
ECM
EIF
EMOBN
FYUFA
HMCUK
M1P
NPM
PHGZT
PROAC
PSQYO
SV3
UKHRP
K9.
7X8
7QL
7T5
C1K
H94
-5E
-5G
-BR
3V.
ABVAZ
ACRMQ
ADINQ
AFGXO
AFNRJ
C24
5PM
ID FETCH-LOGICAL-b607t-447e29fc058ad1cb7f55ccc87b3f32b0e57b4490714159183a2df4e9541bcf2e3
IEDL.DBID RBZ
ISSN 1364-8535
1466-609X
IngestDate Thu Aug 21 18:06:27 EDT 2025
Wed May 22 07:12:12 EDT 2024
Fri Jul 11 09:58:18 EDT 2025
Fri Jul 11 12:13:13 EDT 2025
Sun Jun 29 16:11:32 EDT 2025
Tue Jun 17 20:36:03 EDT 2025
Tue Jun 10 20:29:47 EDT 2025
Thu Apr 03 07:04:57 EDT 2025
Thu Apr 24 22:58:34 EDT 2025
Tue Jul 01 04:22:52 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b607t-447e29fc058ad1cb7f55ccc87b3f32b0e57b4490714159183a2df4e9541bcf2e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
OpenAccessLink http://dx.doi.org/10.1186/cc8959
PMID 20385017
PQID 504627792
PQPubID 44363
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2887183
biomedcentral_primary_oai_biomedcentral_com_cc8959
proquest_miscellaneous_746085304
proquest_miscellaneous_733357734
proquest_journals_504627792
gale_infotracmisc_A226836641
gale_infotracacademiconefile_A226836641
pubmed_primary_20385017
crossref_primary_10_1186_cc8959
crossref_citationtrail_10_1186_cc8959
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-04-13
PublicationDateYYYYMMDD 2010-04-13
PublicationDate_xml – month: 04
  year: 2010
  text: 2010-04-13
  day: 13
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Critical care (London, England)
PublicationTitleAlternate Crit Care
PublicationYear 2010
Publisher BioMed Central Ltd
National Library of Medicine - MEDLINE Abstracts
BioMed Central
Publisher_xml – name: BioMed Central Ltd
– name: National Library of Medicine - MEDLINE Abstracts
– name: BioMed Central
References M Frankenberger (8389_CR41) 1995; 45
K Asehnoune (8389_CR50) 2006; 34
A Pachot (8389_CR53) 2005; 33
RC Bone (8389_CR1) 1997; 112
JW Haveman (8389_CR12) 2006; 10
G Monneret (8389_CR9) 2006; 32
P Gessler (8389_CR42) 2005; 130
T Volk (8389_CR36) 2003; 24
A Cabié (8389_CR33) 1993; 5
Y Matsuki (8389_CR24) 2007; 26
A Richter (8389_CR11) 1999; 165
J Thibodeau (8389_CR23) 2008; 38
B Passlick (8389_CR26) 1989; 74
JC Strohmeyer (8389_CR19) 2003; 53
JM Handy (8389_CR43) 2010; 65
JMMvan den Berk (8389_CR15) 1997; 63
K Asadullah (8389_CR45) 1995; 2
HW Ziegler-Heitbrock (8389_CR27) 1993; 23
T Fumeaux (8389_CR20) 2006; 32
H Ziegler-Heitbrock (8389_CR35) 1995; 45
CE McCall (8389_CR5) 1993; 91
WG Cheadle (8389_CR14) 1991; 161
G Fingerle (8389_CR29) 1993; 82
OY Kim (8389_CR34) 2009; 13
IJ Elenkov (8389_CR47) 1995; 61
L Ziegler-Heitbrock (8389_CR39) 2007; 81
A Satoh (8389_CR17) 2002; 25
T Fumeaux (8389_CR22) 2002; 166
KU Belge (8389_CR40) 2002; 168
Y Le Tulzo (8389_CR21) 2004; 169
T Fumeaux (8389_CR44) 2004; 30
T Volk (8389_CR46) 2001; 29
KJ Tracey (8389_CR51) 2007; 117
F Geissmann (8389_CR28) 2003; 19
A De Gassart (8389_CR25) 2008; 105
SG Muehlstedt (8389_CR16) 2002; 17
A Franke (8389_CR13) 2008; 7
P Maturana (8389_CR6) 1991; 6
J Skrzeczynska-Moncznik (8389_CR30) 2008; 67
S Weijer (8389_CR52) 2002; 186
GF Zhu (8389_CR48) 1996; 16
F Venet (8389_CR3) 2009; 35
AF Petit-Bertron (8389_CR31) 2005; 29
E Ates (8389_CR37) 2004; 67
JM Cavaillon (8389_CR38) 1992; 38
RS Hotchkiss (8389_CR7) 2006; 6
M Adib-Conquy (8389_CR32) 2006; 34
F Venet (8389_CR18) 2007; 35
A Lekkou (8389_CR10) 2004; 11
M Adib-Conquy (8389_CR2) 2009; 101
M Delgado (8389_CR49) 1999; 162
MJ Hershman (8389_CR8) 1990; 77
C Muñoz (8389_CR4) 1991; 88
18389477 - Eur J Immunol. 2008 May;38(5):1225-30
8642417 - J Neurosci. 1996 Jun 1;16(11):3745-52
11907116 - J Immunol. 2002 Apr 1;168(7):3536-42
18305173 - Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3491-6
7693040 - Blood. 1993 Nov 15;82(10):3170-6
2478233 - Blood. 1989 Nov 15;74(7):2527-34
1862821 - Am J Surg. 1991 Jun;161(6):639-45
19132187 - Thromb Haemost. 2009 Jan;101(1):36-47
16850005 - Crit Care Med. 2006 Sep;34(9):2377-85
12406851 - Am J Respir Crit Care Med. 2002 Dec 1;166(11):1475-82
2317682 - Br J Surg. 1990 Feb;77(2):204-7
15368036 - Intensive Care Med. 2004 Nov;30(11):2028-37
14609565 - Cytokine. 2003 Dec 21;24(6):237-43
18055481 - Interact Cardiovasc Thorac Surg. 2008 Apr;7(2):207-11
14715564 - Clin Diagn Lab Immunol. 2004 Jan;11(1):161-7
17255932 - EMBO J. 2007 Feb 7;26(3):846-54
7690321 - Eur J Immunol. 1993 Sep;23(9):2053-8
15587331 - Acta Gastroenterol Belg. 2004 Jul-Sep;67(3):250-4
12069178 - Shock. 2002 Jun;17(6):443-50
9228382 - Chest. 1997 Jul;112(1):235-43
17568330 - Crit Care Med. 2007 Aug;35(8):1910-7
7583350 - J Inflamm. 1995;45(1):13-26
12370535 - Pancreas. 2002 Oct;25(3):245-50
1423923 - Circ Shock. 1992 Oct;38(2):145-52
7593548 - J Neuroimmunol. 1995 Sep;61(2):123-31
12447760 - J Infect Dis. 2002 Dec 15;186(12):1748-53
16899122 - Crit Care. 2006;10(4):R119
11700410 - Crit Care Med. 2001 Nov;29(11):2137-42
9422205 - Eur J Emerg Med. 1995 Dec;2(4):184-90
15579372 - Cytokine. 2005 Jan 7;29(1):1-12
19638210 - Crit Care. 2009;13(4):R124
16741700 - Intensive Care Med. 2006 Aug;32(8):1175-83
12717692 - Cytometry B Clin Cytom. 2003 May;53(1):54-62
15644645 - Crit Care Med. 2005 Jan;33(1):31-8; discussion 236-7
15028560 - Am J Respir Crit Care Med. 2004 May 15;169(10):1144-51
18201370 - Scand J Immunol. 2008 Feb;67(2):152-9
9973516 - J Immunol. 1999 Feb 15;162(4):2358-67
9210517 - Transplantation. 1997 Jun 27;63(12):1846-8
16790355 - Cytokine. 2006 May;34(3-4):212-8
17273548 - J Clin Invest. 2007 Feb;117(2):289-96
18946659 - Intensive Care Med. 2009 Apr;35(4):678-86
17039247 - Nat Rev Immunol. 2006 Nov;6(11):813-22
15999041 - J Thorac Cardiovasc Surg. 2005 Jul;130(1):54-60
12871640 - Immunity. 2003 Jul;19(1):71-82
17135573 - J Leukoc Biol. 2007 Mar;81(3):584-92
1939659 - J Clin Invest. 1991 Nov;88(5):1747-54
19889110 - Anaesthesia. 2010 Jan;65(1):27-35
7583353 - J Inflamm. 1995;45(1):56-63
16741699 - Intensive Care Med. 2006 Aug;32(8):1106-8
10574102 - Eur J Surg. 1999 Oct;165(10):947-51
7680670 - J Clin Invest. 1993 Mar;91(3):853-61
8142599 - Cytokine. 1993 Sep;5(5):448-53
References_xml – volume: 6
  start-page: 42
  year: 1991
  ident: 8389_CR6
  publication-title: J Crit Care
  doi: 10.1016/0883-9441(91)90032-O
– volume: 16
  start-page: 3745
  year: 1996
  ident: 8389_CR48
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.16-11-03745.1996
– volume: 112
  start-page: 235
  year: 1997
  ident: 8389_CR1
  publication-title: Chest
  doi: 10.1378/chest.112.1.235
– volume: 19
  start-page: 71
  year: 2003
  ident: 8389_CR28
  publication-title: Immunity
  doi: 10.1016/S1074-7613(03)00174-2
– volume: 11
  start-page: 161
  year: 2004
  ident: 8389_CR10
  publication-title: Clin Diagn Lab Immunol
– volume: 67
  start-page: 152
  year: 2008
  ident: 8389_CR30
  publication-title: Scand J Immunol
  doi: 10.1111/j.1365-3083.2007.02051.x
– volume: 61
  start-page: 123
  year: 1995
  ident: 8389_CR47
  publication-title: J Neuroimmunol
  doi: 10.1016/0165-5728(95)00080-L
– volume: 38
  start-page: 1225
  year: 2008
  ident: 8389_CR23
  publication-title: Eur J Immunol
  doi: 10.1002/eji.200737902
– volume: 35
  start-page: 678
  year: 2009
  ident: 8389_CR3
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-008-1337-8
– volume: 81
  start-page: 584
  year: 2007
  ident: 8389_CR39
  publication-title: J Leukoc Biol
  doi: 10.1189/jlb.0806510
– volume: 30
  start-page: 2028
  year: 2004
  ident: 8389_CR44
  publication-title: Intensive Care Medicine
  doi: 10.1007/s00134-004-2429-8
– volume: 35
  start-page: 1910
  year: 2007
  ident: 8389_CR18
  publication-title: Crit Care Med
  doi: 10.1097/01.CCM.0000275271.77350.B6
– volume: 130
  start-page: 54
  year: 2005
  ident: 8389_CR42
  publication-title: J Thorac Cardiovasc Surg
  doi: 10.1016/j.jtcvs.2005.01.008
– volume: 88
  start-page: 1747
  year: 1991
  ident: 8389_CR4
  publication-title: J Clin Invest
  doi: 10.1172/JCI115493
– volume: 23
  start-page: 2053
  year: 1993
  ident: 8389_CR27
  publication-title: Eur J Immunol
  doi: 10.1002/eji.1830230902
– volume: 45
  start-page: 13
  year: 1995
  ident: 8389_CR35
  publication-title: J Inflamm
– volume: 65
  start-page: 27
  year: 2010
  ident: 8389_CR43
  publication-title: Anaesthesia
  doi: 10.1111/j.1365-2044.2009.06161.x
– volume: 33
  start-page: 31
  year: 2005
  ident: 8389_CR53
  publication-title: Crit Care Med
  doi: 10.1097/01.CCM.0000150958.20209.A3
– volume: 166
  start-page: 1475
  year: 2002
  ident: 8389_CR22
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.200203-217OC
– volume: 34
  start-page: 212
  year: 2006
  ident: 8389_CR50
  publication-title: Cytokine
  doi: 10.1016/j.cyto.2006.05.003
– volume: 26
  start-page: 846
  year: 2007
  ident: 8389_CR24
  publication-title: Embo J
  doi: 10.1038/sj.emboj.7601556
– volume: 117
  start-page: 289
  year: 2007
  ident: 8389_CR51
  publication-title: J Clin Invest
  doi: 10.1172/JCI30555
– volume: 53
  start-page: 54
  year: 2003
  ident: 8389_CR19
  publication-title: Cytometry B Clin Cytom
  doi: 10.1002/cyto.b.10031
– volume: 82
  start-page: 3170
  year: 1993
  ident: 8389_CR29
  publication-title: Blood
  doi: 10.1182/blood.V82.10.3170.3170
– volume: 186
  start-page: 1748
  year: 2002
  ident: 8389_CR52
  publication-title: J Infect Dis
  doi: 10.1086/345675
– volume: 13
  start-page: R124
  year: 2009
  ident: 8389_CR34
  publication-title: Crit Care
  doi: 10.1186/cc7980
– volume: 165
  start-page: 947
  year: 1999
  ident: 8389_CR11
  publication-title: Eur J Surg
  doi: 10.1080/110241599750008053
– volume: 67
  start-page: 250
  year: 2004
  ident: 8389_CR37
  publication-title: Acta Gastroenterol Belg
– volume: 45
  start-page: 56
  year: 1995
  ident: 8389_CR41
  publication-title: Journal of Inflammation
– volume: 29
  start-page: 2137
  year: 2001
  ident: 8389_CR46
  publication-title: Crit Care Med
  doi: 10.1097/00003246-200111000-00015
– volume: 2
  start-page: 184
  year: 1995
  ident: 8389_CR45
  publication-title: Eur J Emerg Med
  doi: 10.1097/00063110-199512000-00003
– volume: 10
  start-page: R119
  year: 2006
  ident: 8389_CR12
  publication-title: Crit Care
  doi: 10.1186/cc5017
– volume: 105
  start-page: 3491
  year: 2008
  ident: 8389_CR25
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0708874105
– volume: 38
  start-page: 145
  year: 1992
  ident: 8389_CR38
  publication-title: Circ Shock
– volume: 91
  start-page: 853
  year: 1993
  ident: 8389_CR5
  publication-title: J Clin Invest
  doi: 10.1172/JCI116306
– volume: 34
  start-page: 2377
  year: 2006
  ident: 8389_CR32
  publication-title: Crit Care Med
  doi: 10.1097/01.CCM.0000233875.93866.88
– volume: 162
  start-page: 2358
  year: 1999
  ident: 8389_CR49
  publication-title: J Immunol
  doi: 10.4049/jimmunol.162.4.2358
– volume: 5
  start-page: 448
  year: 1993
  ident: 8389_CR33
  publication-title: Cytokine
  doi: 10.1016/1043-4666(93)90034-3
– volume: 101
  start-page: 36
  year: 2009
  ident: 8389_CR2
  publication-title: Thromb Haemost
  doi: 10.1160/TH08-07-0421
– volume: 24
  start-page: 237
  year: 2003
  ident: 8389_CR36
  publication-title: Cytokine
  doi: 10.1016/S1043-4666(03)00090-5
– volume: 32
  start-page: 1175
  year: 2006
  ident: 8389_CR9
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-006-0204-8
– volume: 74
  start-page: 2527
  year: 1989
  ident: 8389_CR26
  publication-title: Blood
  doi: 10.1182/blood.V74.7.2527.2527
– volume: 169
  start-page: 1144
  year: 2004
  ident: 8389_CR21
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.200309-1329OC
– volume: 168
  start-page: 3536
  year: 2002
  ident: 8389_CR40
  publication-title: J Immunol
  doi: 10.4049/jimmunol.168.7.3536
– volume: 6
  start-page: 813
  year: 2006
  ident: 8389_CR7
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri1943
– volume: 29
  start-page: 1
  year: 2005
  ident: 8389_CR31
  publication-title: Cytokine
– volume: 161
  start-page: 639
  year: 1991
  ident: 8389_CR14
  publication-title: Am J Surg
  doi: 10.1016/0002-9610(91)91247-G
– volume: 17
  start-page: 443
  year: 2002
  ident: 8389_CR16
  publication-title: Shock
  doi: 10.1097/00024382-200206000-00001
– volume: 25
  start-page: 245
  year: 2002
  ident: 8389_CR17
  publication-title: Pancreas
  doi: 10.1097/00006676-200210000-00006
– volume: 63
  start-page: 1846
  year: 1997
  ident: 8389_CR15
  publication-title: Transplantation
  doi: 10.1097/00007890-199706270-00026
– volume: 77
  start-page: 204
  year: 1990
  ident: 8389_CR8
  publication-title: Br J Surg
  doi: 10.1002/bjs.1800770225
– volume: 32
  start-page: 1106
  year: 2006
  ident: 8389_CR20
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-006-0205-7
– volume: 7
  start-page: 207
  year: 2008
  ident: 8389_CR13
  publication-title: Interact Cardiovasc Thorac Surg
  doi: 10.1510/icvts.2007.158899
– reference: 17273548 - J Clin Invest. 2007 Feb;117(2):289-96
– reference: 12406851 - Am J Respir Crit Care Med. 2002 Dec 1;166(11):1475-82
– reference: 12069178 - Shock. 2002 Jun;17(6):443-50
– reference: 7693040 - Blood. 1993 Nov 15;82(10):3170-6
– reference: 7583350 - J Inflamm. 1995;45(1):13-26
– reference: 12871640 - Immunity. 2003 Jul;19(1):71-82
– reference: 18389477 - Eur J Immunol. 2008 May;38(5):1225-30
– reference: 17255932 - EMBO J. 2007 Feb 7;26(3):846-54
– reference: 19889110 - Anaesthesia. 2010 Jan;65(1):27-35
– reference: 12447760 - J Infect Dis. 2002 Dec 15;186(12):1748-53
– reference: 16790355 - Cytokine. 2006 May;34(3-4):212-8
– reference: 17568330 - Crit Care Med. 2007 Aug;35(8):1910-7
– reference: 16741700 - Intensive Care Med. 2006 Aug;32(8):1175-83
– reference: 17039247 - Nat Rev Immunol. 2006 Nov;6(11):813-22
– reference: 9422205 - Eur J Emerg Med. 1995 Dec;2(4):184-90
– reference: 16850005 - Crit Care Med. 2006 Sep;34(9):2377-85
– reference: 16741699 - Intensive Care Med. 2006 Aug;32(8):1106-8
– reference: 15644645 - Crit Care Med. 2005 Jan;33(1):31-8; discussion 236-7
– reference: 7680670 - J Clin Invest. 1993 Mar;91(3):853-61
– reference: 7593548 - J Neuroimmunol. 1995 Sep;61(2):123-31
– reference: 10574102 - Eur J Surg. 1999 Oct;165(10):947-51
– reference: 18201370 - Scand J Immunol. 2008 Feb;67(2):152-9
– reference: 15028560 - Am J Respir Crit Care Med. 2004 May 15;169(10):1144-51
– reference: 8642417 - J Neurosci. 1996 Jun 1;16(11):3745-52
– reference: 18305173 - Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3491-6
– reference: 19132187 - Thromb Haemost. 2009 Jan;101(1):36-47
– reference: 8142599 - Cytokine. 1993 Sep;5(5):448-53
– reference: 15368036 - Intensive Care Med. 2004 Nov;30(11):2028-37
– reference: 15579372 - Cytokine. 2005 Jan 7;29(1):1-12
– reference: 9210517 - Transplantation. 1997 Jun 27;63(12):1846-8
– reference: 15587331 - Acta Gastroenterol Belg. 2004 Jul-Sep;67(3):250-4
– reference: 2478233 - Blood. 1989 Nov 15;74(7):2527-34
– reference: 1862821 - Am J Surg. 1991 Jun;161(6):639-45
– reference: 2317682 - Br J Surg. 1990 Feb;77(2):204-7
– reference: 9228382 - Chest. 1997 Jul;112(1):235-43
– reference: 15999041 - J Thorac Cardiovasc Surg. 2005 Jul;130(1):54-60
– reference: 1423923 - Circ Shock. 1992 Oct;38(2):145-52
– reference: 1939659 - J Clin Invest. 1991 Nov;88(5):1747-54
– reference: 12370535 - Pancreas. 2002 Oct;25(3):245-50
– reference: 16899122 - Crit Care. 2006;10(4):R119
– reference: 9973516 - J Immunol. 1999 Feb 15;162(4):2358-67
– reference: 7583353 - J Inflamm. 1995;45(1):56-63
– reference: 11907116 - J Immunol. 2002 Apr 1;168(7):3536-42
– reference: 14715564 - Clin Diagn Lab Immunol. 2004 Jan;11(1):161-7
– reference: 17135573 - J Leukoc Biol. 2007 Mar;81(3):584-92
– reference: 7690321 - Eur J Immunol. 1993 Sep;23(9):2053-8
– reference: 18946659 - Intensive Care Med. 2009 Apr;35(4):678-86
– reference: 14609565 - Cytokine. 2003 Dec 21;24(6):237-43
– reference: 18055481 - Interact Cardiovasc Thorac Surg. 2008 Apr;7(2):207-11
– reference: 11700410 - Crit Care Med. 2001 Nov;29(11):2137-42
– reference: 12717692 - Cytometry B Clin Cytom. 2003 May;53(1):54-62
– reference: 19638210 - Crit Care. 2009;13(4):R124
SSID ssj0017863
Score 2.2863016
Snippet Decreased expression of human leukocyte antigen class II (HLA-DR) on monocytes is a hallmark of altered immune status in patients with a systemic inflammatory...
Introduction Decreased expression of human leukocyte antigen class II (HLA-DR) on monocytes is a hallmark of altered immune status in patients with a systemic...
INTRODUCTION: Decreased expression of human leukocyte antigen class II (HLA-DR) on monocytes is a hallmark of altered immune status in patients with a systemic...
SourceID pubmedcentral
biomedcentral
proquest
gale
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage R61
SubjectTerms Aged
Aorta, Abdominal - immunology
Aorta, Abdominal - surgery
Carotid Arteries - immunology
Carotid Arteries - surgery
Case-Control Studies
Development and progression
Down-Regulation - immunology
Female
Flow Cytometry
Gene expression
Gene Expression - immunology
Genetic aspects
Genetic regulation
HLA class II antigens
HLA-DR Antigens - biosynthesis
HLA-DR Antigens - immunology
Humans
Inflammation
Lipopolysaccharide Receptors - metabolism
Male
Middle Aged
Monocytes
Monocytes - cytology
Monocytes - immunology
Monocytes - metabolism
Observations
Physiological aspects
Polymerase Chain Reaction - methods
Properties
Systemic Inflammatory Response Syndrome - immunology
Systemic Inflammatory Response Syndrome - metabolism
Title Differential down-regulation of HLA-DR on monocyte subpopulations during systemic inflammation
URI https://www.ncbi.nlm.nih.gov/pubmed/20385017
https://www.proquest.com/docview/504627792
https://www.proquest.com/docview/733357734
https://www.proquest.com/docview/746085304
http://dx.doi.org/10.1186/cc8959
https://pubmed.ncbi.nlm.nih.gov/PMC2887183
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIiEuqLzTluIDiJNF4mdyXCjVClEOiEoVB6zYsdVKq2zV3T3w7xnH2VCv4MIx8jhKvpnJzGQ8MwBv6lK4LsiSatt5KgRzFMOglqIpdgENhuVDi43zr2p-IT5fyss9IH_P4Fe1eu9c3cjmHtxnAq1fjMc__JjyBLoeZqVVXAmKhkeO04P-7NupY19k5mf3I3zHCuUnJO-YnLMDeDT6imSWmPsY9nz_BB6cj9nwp_DzdJxuglq6IB3G0_Q2jZZHsMkykPmXGT39RvAChW3pfq09WW3szTSza0VSlSJJ_ZyvHUF5QxFJ5YzP4OLs0_ePczrOS6BWlXqNSGvPmuBKWbdd5awOUjqEQVseOLOll9oK0cSSJXRiUJdb1gXhGykq6wLz_Dns98vevwSigvMKQz9bDgEcht-trx1TXcuVDVwUwDJYzU3qjWFit-p8BRXHJF4U8HaLvXFjB_I4CGNhhkikVhPd64lue99dineRdSYqId7BtWMtAT58bGdlZuhU1lwpURVwnFGi8rhs-WjLfDMq78rIWLCrdcMKINNq3BjPo_V-uVkZzTmXWkcg_kkiFLqzvESSF0mYppdhMR2LwluAzsQsQzFf6a-vht7fDI0Ccu7wf_A_gofp7IOgFT-G_fXtxr9Cl2ptT4ZfESeDbv0GfoQl0Q
linkProvider BioMedCentral
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LbtQw0IIiAZeKZ0lbqA8gTobEz-S4tFQL7PZQtVLFASt2bFFpla26uwf-vuPYm25W6oVjNGMrmYdnJp4HQh_LnNvGi5wo0zjCObUEwqCagCm2HgyGYV2LjemZHF_yn1fiKv1wC7UwNjX4D3lPXzYr0Gfdsb3OFovKXsqv1paVqB6jJ0oIFSYYnH_73d8iqLKbpFYwyQmYJZFmC92v26pynw2M0_YRvWGjhvmTGwbp9AXaTZ4kHsV3fYkeufYVejpNd-Wv0Z-TNPsEdHiGG4i2yW0cPA-swHOPx5MROTnH8ACiOLf_lg4vVuamn-i1wLGGEcduz9cWgzSCAMVixzfo8vT7xfGYpGkKxMhcLYEPytHK21yUdVNYo7wQFsigDPOMmtwJZTivQkETuDig6TVtPHeV4IWxnjr2Fu2089a9Q1h66yQEhibvwjsIzmtXWiqbmknjGc8QHZBV38TOGTr0sh5CgKk68iJDn9a01zb1Jw9jMma6i1NK2eMd9XjrfbcxPgfW6aCisIOtU6UBvHxodqVH4HKWTEpeZOhwgAmqZQfggzXzdVLthRahnFepimYI99CwMGSrtW6-WmjFGBNKBUI8iMIlOLssB5S9KEz9x9BwWQvCmyE1ELMBFYeQ9vpv1xmcgskAzu3_D_2P0LPxxXSiJz_Ofh2g5zFLgpOCHaKd5e3KvQfna2k-dBp2BzgwNAM
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBUXVJ4NLdQHECfTxM_kuLCsFmgrVFGp4oAVO7aoWGVX3d1D_z3j2Bs2K3HhlsjjKJlHZkaemQ-hN2XObeNFTpRpHOGcWgJpUE3AFVsPDsOwbsTG-YWcXvEv1-I64ZyGXhibBvyHuqf32x3os-63DRf29-mi8dHaS3lqbVmJ6j56oIRQwTIvP_zojxFU2UGpFUxyAn5JJHChv_t22txnA--0-4_eclLDAsotjzQ5QI9SKIlHUfaP0T3XPkH75-mw_Cn6OU7gJ2DEM9xAuk1uI_I8yALPPZ6ejcj4EsMN6OLc3q0cXq7Noof0WuLYxIjjuOcbi0EdQYNit-MzdDX59P3jlCQ4BWJkrlYgCOVo5W0uyroprFFeCAtsUIZ5Rk3uhDKcV6GjCWIcMPWaNp67SvDCWE8de4722nnrDhGW3joJmaHJu_wOsvPalZbKpmbSeMYzRAds1Ys4OkOHYdbDFZCqjrLI0NsN77VNA8oDTsZMd4lKKXu6k55u89xdindBdDrYaNCYOrUawMuHaVd6BDFnyaTkRYaOB5RgW3awfLQRvk62vdQi9PMqVdEM4X41bAzlaq2br5daMcaEUoER_yThEqJdlgPJi6hM_cfQcFoLypshNVCzAReHK-3Nr240OAWfAZJ7-T_8P0H738YTffb54usRehirJDgp2DHaW92u3SsIvlbmdWdgfwClhTPO
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differential+down-regulation+of+HLA-DR+on+monocyte+subpopulations+during+systemic+inflammation&rft.jtitle=Critical+care+%28London%2C+England%29&rft.au=Kim%2C+Oh+Yoen&rft.au=Monsel%2C+Antoine&rft.au=Bertrand%2C+Mich%C3%A8le&rft.au=Coriat%2C+Pierre&rft.date=2010-04-13&rft.pub=BioMed+Central+Ltd&rft.issn=1364-8535&rft.volume=14&rft.spage=R61&rft_id=info:doi/10.1186%2Fcc8959&rft.externalDocID=A226836641
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1364-8535&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1364-8535&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1364-8535&client=summon